IL255898A - Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases - Google Patents
Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseasesInfo
- Publication number
- IL255898A IL255898A IL255898A IL25589817A IL255898A IL 255898 A IL255898 A IL 255898A IL 255898 A IL255898 A IL 255898A IL 25589817 A IL25589817 A IL 25589817A IL 255898 A IL255898 A IL 255898A
- Authority
- IL
- Israel
- Prior art keywords
- initiation
- inhibition
- translation
- diseases
- treatment
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000000977 initiatory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169376P | 2015-06-01 | 2015-06-01 | |
| PCT/US2016/035288 WO2016196644A1 (en) | 2015-06-01 | 2016-06-01 | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL255898A true IL255898A (en) | 2018-01-31 |
Family
ID=56118071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL255898A IL255898A (en) | 2015-06-01 | 2017-11-26 | Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10537558B2 (https=) |
| EP (1) | EP3303332A1 (https=) |
| JP (1) | JP6707630B2 (https=) |
| CN (1) | CN108349962A (https=) |
| BR (1) | BR112017025851A2 (https=) |
| CA (1) | CA3025492A1 (https=) |
| IL (1) | IL255898A (https=) |
| MX (1) | MX2017015456A (https=) |
| WO (1) | WO2016196644A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3303332A1 (en) | 2015-06-01 | 2018-04-11 | Bantam Pharmaceutical, LLC | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
| MX2019006296A (es) * | 2016-11-30 | 2019-11-12 | Bantam Pharmaceutical Llc | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. |
| AU2017366901B2 (en) * | 2016-11-30 | 2022-09-29 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| EP3778583B1 (en) | 2018-03-30 | 2025-06-18 | Sumitomo Chemical Company, Limited | Heterocyclic compound and arthropod pest control composition containing same |
| WO2019236966A2 (en) | 2018-06-07 | 2019-12-12 | Bantam Pharmaceutical, Llc | Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| CN110950848B (zh) * | 2018-09-27 | 2024-03-26 | 徐诺药业 | 新型氨基吡唑类衍生物的合成与应用 |
| WO2020243582A1 (en) * | 2019-05-31 | 2020-12-03 | Bantam Pharmaceutical, Llc | Methods for making thiszolylpyrazole carboxylic acids and intermediates therefor |
| JP7085697B2 (ja) | 2019-11-01 | 2022-06-16 | ユニマテック株式会社 | 含フッ素ピリミジン化合物およびその製造方法 |
| AU2021230289A1 (en) * | 2020-03-03 | 2022-09-29 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342851A (en) * | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
| IT1301968B1 (it) * | 1998-07-30 | 2000-07-20 | Zambon Spa | Derivati di eritromicina ad attivita' antibiotica |
| DE60006057T2 (de) * | 1999-12-03 | 2004-05-27 | Pfizer Products Inc., Groton | Heteroarylphenylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| US6900219B2 (en) | 2002-04-04 | 2005-05-31 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
| AU2004228057A1 (en) | 2003-04-03 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| EP1618099A4 (en) | 2003-04-18 | 2008-07-16 | Merck & Co Inc | BIARYLSUBSTITUTED DIAZOLE, OXAZOLE AND IMIDAZOLE AS SODIUM CHANNEL BLOCKERS |
| WO2007138110A2 (en) * | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| US8642597B2 (en) | 2007-08-27 | 2014-02-04 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| SI2275414T1 (sl) | 2008-04-28 | 2015-10-30 | Kyorin Pharmaceutical Co., Ltd., | Ciklopentilakrilamidni derivat |
| EP2651405A2 (en) * | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| US9409901B2 (en) | 2012-10-22 | 2016-08-09 | Bantam Pharmaceutical, Llc | Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E |
| JP6434989B2 (ja) | 2014-03-27 | 2018-12-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ピリジルピペリジン |
| US10125139B2 (en) | 2015-04-24 | 2018-11-13 | Syngenta Crop Protection Ag | Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocycles |
| EP3303332A1 (en) | 2015-06-01 | 2018-04-11 | Bantam Pharmaceutical, LLC | Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto |
-
2016
- 2016-06-01 EP EP16728546.9A patent/EP3303332A1/en not_active Withdrawn
- 2016-06-01 CN CN201680045318.9A patent/CN108349962A/zh active Pending
- 2016-06-01 WO PCT/US2016/035288 patent/WO2016196644A1/en not_active Ceased
- 2016-06-01 MX MX2017015456A patent/MX2017015456A/es unknown
- 2016-06-01 US US15/578,585 patent/US10537558B2/en active Active
- 2016-06-01 CA CA3025492A patent/CA3025492A1/en not_active Abandoned
- 2016-06-01 BR BR112017025851-0A patent/BR112017025851A2/pt not_active Application Discontinuation
- 2016-06-01 JP JP2018515175A patent/JP6707630B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-26 IL IL255898A patent/IL255898A/en unknown
-
2020
- 2020-01-21 US US16/748,429 patent/US11602526B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016196644A1 (en) | 2016-12-08 |
| BR112017025851A2 (pt) | 2018-10-16 |
| EP3303332A1 (en) | 2018-04-11 |
| CN108349962A (zh) | 2018-07-31 |
| US10537558B2 (en) | 2020-01-21 |
| JP2018521119A (ja) | 2018-08-02 |
| US20200261424A1 (en) | 2020-08-20 |
| JP6707630B2 (ja) | 2020-06-10 |
| US11602526B2 (en) | 2023-03-14 |
| CA3025492A1 (en) | 2016-12-08 |
| US20180311218A1 (en) | 2018-11-01 |
| MX2017015456A (es) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255898A (en) | Converted pyrazole and pyrrole compounds and methods of using them to prevent the onset of conversion and treat related diseases | |
| IL266930A (en) | Modified pyrazole compounds and methods of using them for the treatment of hyperproliferative diseases | |
| IL266931A (en) | Methods of using modified pyrazole and pyrazole compounds for the treatment of hyperproliferative diseases | |
| PL4122464T3 (pl) | Kombinacje terapeutyczne do leczenia chorób wątroby | |
| ZA201807084B (en) | Methods of treatment of cholestatic diseases | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| EP3668993A4 (en) | HEPATIC DISEASE TREATMENT METHODS | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| IL275321A (en) | Treatment of diseases associated with the expression of DUX4 | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL254568A0 (en) | Compounds and forms for the treatment of female sexual disorders | |
| ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
| IL261277A (en) | Combination therapies for treatment of spinal muscular atrophy | |
| IL320533A (en) | Methods and compositions for treating disorders and diseases involving RDH12 | |
| EP3340974A4 (en) | METHODS OF TREATING DISEASES | |
| ZA201705877B (en) | Method of treating diseases | |
| IL253847A0 (en) | Methods of treating diseases | |
| HUE054420T2 (hu) | Folyamatos eljárás terápiás fehérje heterogenitásának csökkentésére | |
| IL279497A (en) | Treatment of protein in the urine | |
| GB201612043D0 (en) | Composition for treatment of disorders | |
| EP3251699A4 (en) | Composition and method for treatment of neuropsychiatric disorders | |
| SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases | |
| IL265596A (en) | Methods for treating ocular disease using inhibitors of csf-1r | |
| ZA202001927B (en) | Method for treating tnf alpha-related diseases | |
| IL252543A0 (en) | Compounds for the treatment of degenerative retinal tissues |